Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

Novartis Pharmaceuticals67 enrolled

Overview

The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

imatinib mesylateDRUG

TreosulfaneDRUG

etoricoxibDRUG

pioglitazoneDRUG

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration). * Patients must have increasing PSA levels (within 3 months prior to enrollment) with at least two consecutively increasing PSA levels. * PSA value before inclusion must be at least 5 ng/ml * At least 18 years of age. * At least capable of self care and up of at least 50% of waking hours (ECOG performance status 0 - 2), adequate bone marrow function and lab results. Exclusion criteria: * Change of hormone therapy within 6 weeks prior inclusion * Prior chemotherapy * Therapy with Imatinib, or therapy with other inhibitors of tyrosinkinase. * Second neoplasm diagnosed within 5 years before study start. * Patients who require therapy with warfarin * Known diagnosis of HIV, hepatitis B, or hepatitis C infection. * Severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency * Surgical therapy within 4 weeks before inclusion. * Prior therapy with isotopes strontium or rhenium. * Radiation therapy to \> 25% of bone marrow within 4 weeks before inclusion. * Treatment with other experimental substances within 30 days before study start. Other protocol-defined inclusion/exclusion criteria may apply

Locations (10)

Novartis Investigative Site

Bad Reichenhall, Germany

Novartis Investigative Site

Bonn, Germany

Novartis Investigative Site

Hamburg, Germany

Novartis Investigative Site

Hamburg, Germany

Outcomes

Primary Outcomes

PSA Response Rate

To investigate the effect of a treatment with Imatinib mesylate, Pioglitazone , Etoricoxib, and Dexamethasone in combination with metronomic chemotherapy (Treosulfane) on the PSA response rate in patients with hormone refractory prostate cancer. A patient will be defined as a responder if a PSA decline of at least 50%, which must be confirmed by a second PSA value 4 weeks later, is observed. A patient will be defined as a non-responder if PSA has not decreased during treatment. Non-response is defined as a 25% increase over the baseline on-study which is confirmed (equal or more) by a second value 4 weeks apart. The absolute increase must account for \> 5 ng/ml.

Time frame: up to 24 weeks

Secondary Outcomes

Time to PSA Response

Time to PSA response, defined as the time from first administration of study drugs to the first PSA value of a confirmed PSA response. Non-responders will be censored with date of final visit/premature discontinuation for the analysis. Median time to PSA response was not achieved

Time frame: every 4 weeks up to 24 weeks

Time to Progression-free Survival

Progression-free survival, defined as the time from first administration of study drugs to the first PSA value of a PSA non-responder. Responders will be censored with date of PSA response for the analysis. The median time to PSA progression free survival was not achieved

Time frame: every 4 weeks up to 24 weeks

Overall Survival Rate

Overall survival (OS) is defined as time from randomization to death from any cause or last date known alive. The median time to overall survival rate was not achieved

Time frame: every 4 weeks up to 24 weeks

Quality of Life Assessed With EORTC-30

Health-related quality of life was assessed with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-30) questionnaire and was presented descriptively. The EORTC QLQ-C30 is a questionnaire including following sub-scales: global health status, functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social activity), symptom scales (fatigue, nausea and vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better quality of life on global health status and functional scales and worse quality of life on symptom scales and financial difficulty scale.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.